Effect of Oral Moxifloxacin vs Intravenous Ertapenem Plus Oral Levofloxacin for Treatment of Uncomplicated Acute Appendicitis: The APPAC II Randomized Clinical Trial.


Journal

JAMA
ISSN: 1538-3598
Titre abrégé: JAMA
Pays: United States
ID NLM: 7501160

Informations de publication

Date de publication:
26 01 2021
Historique:
pubmed: 12 1 2021
medline: 11 2 2021
entrez: 11 1 2021
Statut: ppublish

Résumé

Antibiotics are an effective and safe alternative to appendectomy for managing uncomplicated acute appendicitis, but the optimal antibiotic regimen is not known. To compare oral antibiotics with combined intravenous followed by oral antibiotics in the management of computed tomography-confirmed uncomplicated acute appendicitis. The Appendicitis Acuta (APPAC) II multicenter, open-label, noninferiority randomized clinical trial was conducted from April 2017 until November 2018 in 9 Finnish hospitals. A total of 599 patients aged 18 to 60 years with computed tomography-confirmed uncomplicated acute appendicitis were enrolled in the trial. The last date of follow-up was November 29, 2019. Patients randomized to receive oral monotherapy (n = 295) received oral moxifloxacin (400 mg/d) for 7 days. Patients randomized to receive intravenous antibiotics followed by oral antibiotics (n = 288) received intravenous ertapenem (1 g/d) for 2 days followed by oral levofloxacin (500 mg/d) and metronidazole (500 mg 3 times/d) for 5 days. The primary end point was treatment success (≥65%) for both groups, defined as discharge from hospital without surgery and no recurrent appendicitis during 1-year follow-up, and to determine whether oral antibiotics alone were noninferior to intravenous and oral antibiotics, with a margin of 6% for difference. Among 599 patients who were randomized (mean [SD] age, 36 [12] years; 263 [44%] women), 581 (99.7%) were available for the 1-year follow-up. The treatment success rate at 1 year was 70.2% (1-sided 95% CI, 65.8% to ∞) for patients treated with oral antibiotics and 73.8% (1-sided 95% CI, 69.5% to ∞) for patients treated with intravenous followed by oral antibiotics. The difference was -3.6% ([1-sided 95% CI, -9.7% to ∞]; P = .26 for noninferiority), with the confidence limit exceeding the noninferiority margin. Among adults with uncomplicated acute appendicitis, treatment with 7 days of oral moxifloxacin compared with 2 days of intravenous ertapenem followed by 5 days of levofloxacin and metronidazole resulted in treatment success rates greater than 65% in both groups, but failed to demonstrate noninferiority for treatment success of oral antibiotics compared with intravenous followed by oral antibiotics. ClinicalTrials.gov Identifier: NCT03236961; EudraCT Identifier: 2015-003633-10.

Identifiants

pubmed: 33427870
pii: 2775227
doi: 10.1001/jama.2020.23525
pmc: PMC7802006
doi:

Substances chimiques

Anti-Bacterial Agents 0
Metronidazole 140QMO216E
Levofloxacin 6GNT3Y5LMF
Ertapenem G32F6EID2H
Moxifloxacin U188XYD42P

Banques de données

ClinicalTrials.gov
['NCT03236961']

Types de publication

Comparative Study Equivalence Trial Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

353-362

Commentaires et corrections

Type : CommentIn

Références

World J Surg. 2017 Sep;41(9):2411
pubmed: 28050666
World J Surg. 2006 Jun;30(6):1033-7
pubmed: 16736333
Ann Surg. 2019 Dec;270(6):1028-1040
pubmed: 30720508
Br J Surg. 2017 Jan;104(1):52-61
pubmed: 27686365
Colorectal Dis. 2012 Mar;14(3):325-30
pubmed: 21689302
Br J Surg. 2017 Sep;104(10):1355-1361
pubmed: 28677879
BMC Surg. 2018 Dec 17;18(1):117
pubmed: 30558607
Surg Infect (Larchmt). 2010 Feb;11(1):79-109
pubmed: 20163262
Br J Surg. 2019 Oct;106(11):1542-1548
pubmed: 31386199
JAMA. 2015 Jun 16;313(23):2340-8
pubmed: 26080338
J Trauma Acute Care Surg. 2019 Apr;86(4):722-736
pubmed: 30516592
Ann Emerg Med. 2017 Jul;70(1):1-11.e9
pubmed: 27974169
N Engl J Med. 2020 Nov 12;383(20):1907-1919
pubmed: 33017106
J Am Coll Surg. 2014 Aug;219(2):272-9
pubmed: 24951281
JAMA. 2018 Sep 25;320(12):1259-1265
pubmed: 30264120
World J Emerg Surg. 2020 Apr 15;15(1):27
pubmed: 32295644
Br J Surg. 2009 May;96(5):473-81
pubmed: 19358184
JAMA. 2015 Jun 16;313(23):2371-2
pubmed: 26080342
Lancet. 2011 May 7;377(9777):1573-9
pubmed: 21550483
Dis Colon Rectum. 2016 Jun;59(6):529-34
pubmed: 27145310
J Am Coll Surg. 2016 Mar;222(3):309-14
pubmed: 26712246
Br J Surg. 2017 Dec;104(13):1785-1790
pubmed: 28925502
J Trauma Acute Care Surg. 2017 Jun;82(6):1129-1137
pubmed: 28338596
Int J Antimicrob Agents. 2013 Jan;41(1):57-64
pubmed: 23153963
Abdom Radiol (NY). 2021 Mar;46(3):948-959
pubmed: 32914350
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
BMJ Open. 2018 Nov 3;8(11):e023623
pubmed: 30391919
JAMA Surg. 2020 Apr 1;155(4):283-289
pubmed: 32074268
Int J Colorectal Dis. 2015 Sep;30(9):1229-34
pubmed: 25989930
Br J Surg. 2012 Apr;99(4):532-9
pubmed: 22290281
Clin Infect Dis. 2011 Dec;53(11):1074-80
pubmed: 21998288
JAMA. 2020 Aug 11;324(6):581-593
pubmed: 32730561
Br J Surg. 2021 Jun 22;108(6):717-726
pubmed: 34157090
Br J Surg. 2016 May;103(6):656-667
pubmed: 26990957
Ann Surg. 2007 Jun;245(6):886-92
pubmed: 17522514
PLoS One. 2019 Jul 25;14(7):e0220202
pubmed: 31344073

Auteurs

Suvi Sippola (S)

Division of Digestive Surgery and Urology, Turku University Hospital, Turku, Finland.
Department of Surgery, University of Turku, Turku, Finland.

Jussi Haijanen (J)

Division of Digestive Surgery and Urology, Turku University Hospital, Turku, Finland.
Department of Surgery, University of Turku, Turku, Finland.
Department of Surgery, Satakunta Central Hospital, Pori, Finland.

Juha Grönroos (J)

Division of Digestive Surgery and Urology, Turku University Hospital, Turku, Finland.
Department of Surgery, University of Turku, Turku, Finland.

Tero Rautio (T)

Department of Surgery, Oulu University Hospital, Oulu, Finland.
Medical Research Center Oulu, University of Oulu, Finland.

Pia Nordström (P)

Department of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital, Tampere, Finland.
Faculty of Medicine and Health Technology, University of Tampere, Tampere, Finland.

Tuomo Rantanen (T)

Department of Surgery, Kuopio University Hospital, Kuopio, Finland.
Department of Surgery, Institute of Clinical Medicine, University of Eastern Finland.

Tarja Pinta (T)

Department of Surgery, Seinäjoki Central Hospital, Seinäjoki, Finland.

Imre Ilves (I)

Department of Surgery, Mikkeli Central Hospital, Mikkeli, Finland.

Anne Mattila (A)

Department of Surgery, Jyväskylä Central Hospital, Jyväskylä, Finland.

Jukka Rintala (J)

Department of Surgery, Oulu University Hospital, Oulu, Finland.
Department of Surgery, Rovaniemi Central Hospital, Rovaniemi, Finland.

Eliisa Löyttyniemi (E)

Department of Biostatistics, University of Turku, Turku, Finland.

Saija Hurme (S)

Department of Biostatistics, University of Turku, Turku, Finland.

Ville Tammilehto (V)

Department of Radiology, Turku University Hospital, Turku, Finland.

Harri Marttila (H)

Department of Hospital Hygiene & Infection Control, Turku University Hospital, Turku, Finland.

Sanna Meriläinen (S)

Department of Surgery, Oulu University Hospital, Oulu, Finland.
Medical Research Center Oulu, University of Oulu, Finland.

Johanna Laukkarinen (J)

Department of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital, Tampere, Finland.
Faculty of Medicine and Health Technology, University of Tampere, Tampere, Finland.

Eeva-Liisa Sävelä (EL)

Department of Surgery, Satakunta Central Hospital, Pori, Finland.

Heini Savolainen (H)

Department of Surgery, Kuopio University Hospital, Kuopio, Finland.

Tomi Sippola (T)

Department of Surgery, Seinäjoki Central Hospital, Seinäjoki, Finland.

Markku Aarnio (M)

Department of Surgery, Jyväskylä Central Hospital, Jyväskylä, Finland.

Hannu Paajanen (H)

Department of Surgery, Mikkeli Central Hospital, Mikkeli, Finland.

Paulina Salminen (P)

Division of Digestive Surgery and Urology, Turku University Hospital, Turku, Finland.
Department of Surgery, University of Turku, Turku, Finland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH